Additional mutations in genes involved in the regulation of epigenetic (ASXL1, EZH2, TET2, DNMT3A, IDH1/2), mRNA splicing (SRSF2, SF3B1, U2AF1, ZRSR2), gene transcription (TP53, NFE2, IKZF1) or non-JAK/STAT signaling pathways (NRAS, KRAS, CBL)13,14 complement the MPN molecular landscape. The gene discussed is KRAS; the disease is myeloproliferative neoplasm.